The Choice Between Immunotherapy and TKIs for Liver Cancer – Targeted Oncology
The Choice Between Immunotherapy and TKIs for Liver CancerTargeted OncologyOptions for treating patients with hepatocellular carcinoma (HCC) may currently be limited, with most physicians turning to a tyrosine kinase inhibitor (TKI) for advanced diseas… Continue reading
